Asgard Therapeutics AB is a biotechnology company based in Lund, specializing in the development of cancer immunotherapy through direct cell reprogramming. The company focuses on advancing cancer treatment by leveraging its expertise in drug development and immunotherapy. Asgard Therapeutics has a strong leadership team comprised of industry experts, which includes the recent appointment of an immunology expert as Chief Development Officer.
The company conducts research on dendritic cell diversity and its role in anti-tumor immunity, employing in vivo approaches for dendritic cell reprogramming. Asgard Therapeutics emphasizes innovative screening methods for transcription factors, which are critical in their research and development processes. Additionally, the company has been recognized for its contributions to the field, being a recipient of the EIC Transition Grant and actively engaging in recent scientific publications.